SinuSonic celebrates milestone sales and research achievements

The hand-held medical device sold 10k units in 2020 and embarked on a groundbreaking research initiative

SinuSonic, a first of its kind medical device for natural relief of nasal congestion using acoustic humming and oscillating pressure, is celebrating significant sales and research milestones to start 2021. SinuSonic sold more than 10,000 devices globally in 2020, including to happy customers in all 50 states. Additionally, independent researchers with the Medical University of South Carolina are currently studying SinuSonic’s effectiveness in preventing viral upper respiratory infections such as influenza, rhinovirus, and coronaviruses.

“2020 showed us the importance of embracing our health, as well as innovative wellness practices that can become a part of our daily routines,” said SinuSonic inventor and renowned pulmonologist, Dr. Richard K. Bogan. “SinuSonic is helping chronic sinus sufferers bust congestion in a way that’s quick, economic, and holistic. Thousands of users felt the difference for themselves last year and I’m encouraged to reach new corners of the globe in 2021.”

The American-made SinuSonic clears sinuses by combining gentle pressure and vibration to stimulate a user’s nose. The user simply breathes through the nose into the device for two minutes, twice a day. Similar treatments have long been used by pulmonologists to clear the lungs of patients with cystic fibrosis. When applied to the nasal passages, an independent study found more than 80 percent of study participants experienced relief from their chronic sinus congestion. Nearly 90% said they would want their family and friends to try it, too.

“It is so encouraging to know those 10,000 devices sold translates into 10,000 opportunities to enhance the quality of life for chronic congestion sufferers,” said Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and Co-Medical Director at SinuSonic. “Now, as we embark on new research opportunities with SinuSonic in 2021, we are hopeful to be a part of the global conversation about innovative, holistic solutions for viral upper respiratory infections that continue to plague our world.”

Prior SinuSonic research has shown that the acoustic vibrations trigger an increase in nitric oxide (NO) release from the sinuses and nasal passages. NO is a molecule with known antiviral and antibacterial properties. Medical studies unrelated to SinuSonic are already researching the positive effects of externally administering nitric oxide as a potential treatment for upper respiratory infections, including COVID-19. This latest SinuSonic independent study is taking the theory a step further by measuring the body’s ability to prevent infection through harnessing its own natural production of nitric oxide spurred by using the SinuSonic device.

“We are eager to see whether regular use of SinuSonic during cold and flu season can decrease the chance of getting sick from one of these viruses,” said Schlosser.

To learn more about the double-patented device, including the science behind this drug-free, mess-free congestion solution, visit


Dr. Rodney Schlosser

Dr. Schlosser is the Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC). After graduating from the U.S. Military Academy at West Point and serving for four years on active duty, Dr. Schlosser received his medical degree from the Mayo Clinic. He completed his ENT residency at the University of Virginia and then embarked on a one year fellowship at the University of Pennsylvania devoted to the treatment of advanced sinus disease. 

Dr. Schlosser authored a textbook on the management of sinus problems and more than 200 articles and chapters on sinus and nasal topics. He regularly travels the world to speak and teach courses on the latest medical techniques, including endoscopic sinus surgery and computerized image-guided surgery. Dr. Schlosser focuses on difficult adult and pediatric sinus cases involving a host of conditions including nasal obstruction, revision surgeries, sinonasal tumors, encephaloceles/cerebrospinal fluid leaks, severe nasal polyposis, smell and taste disorders, and congenital nasal disorders. 

Dr. Zachary Soler

Dr. Soler is an Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina. He attended medical school at Wake Forest University, followed by an ENT residency at Oregon Health and Sciences University. He then completed a fellowship dedicated solely to rhinology and endoscopic sinus surgery at Harvard Medical School. Remaining at Harvard, Dr. Soler devoted an additional year of study, earning a master’s degree in epidemiology.  

Dr Soler has published over 150 peer-reviewed articles, most of which focus on outcomes after treatment of diseases of the nose and sinuses. He is a principal investigator on a multi-center NIH study examining outcomes in patients with chronic sinusitis. Dr. Soler’s clinical practice is dedicated primarily to diseases of the nose, sinuses, and skull base. He has particular expertise with difficult-to-manage cases of sinusitis, revision sinus surgery, and surgical treatment of sinonasal tumors. 

Though Dr. Schlosser and Dr. Soler are currently employed by the Medical University of South Carolina (MUSC), neither the Medical University of South Carolina, nor any affiliated organizations shall be responsible for information provided herein under any theory of liability or indemnity.


Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever patented nasal congestion relief device to use acoustic vibrations to help provide nasal congestion relief. SinuSonic is designed in the U.S. with parts molded in the U.S. and assembled in an FDA-registered facility in Columbia, South Carolina. Since launching in July 2019, SinuSonic is being used in all 50 states. For more information and to view instructional videos, visit 

Media Contact: The Brandon Agency| Allison Eckley ||336-414-4972